来自威康桑格研究所、伦敦帝国理工学院、美国哈佛大学的研究人员及其合作者利用CRISPR prime editing技术在细胞系中创建了多个版本的人类基因组，每个版本都有不同的结构变化。通过基因组测序，他们能够分析这些结构变异对细胞存活的遗传影响。

Prime Medicine, Inc. faces risks in the gene editing sector despite positive developments, caution advised for retail investors. Click for my PRME stock update.

Since the technique was first published in 2019, prime editing has grown with lightning speed, alongside hopes for what it can achieve. Emilie is an assistant editor at the Scientist. She has a ...

Continue reading about off-target effects in this story. Base and Prime Editing Offer Precision CRISPR-based systems that rely on traditional Cas nucleases like Cas9 cut through both strands of DNA ...

Prime Medicine has been given the go-ahead by the FDA for the first human trial of its prime editing technology, which promises to deliver one-shot therapies for a range of severe genetic diseases.

The most complex engineering of human cell lines ever has been achieved by scientists, revealing that our genomes are more ...

to initiate trials of the first-ever prime editing drug. The FDA cleared Prime Medicine’s investigational new drug (IND) application for PM359 for the treatment of chronic granulomatous disease ...

Gene-editing biotech Prime Medicine has priced a follow-on public offering, hoping to raise $140 million to advance its pipeline of one-shot therapies for severe genetic disorders. The Cambridge ...

Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime ...

Prime Medicine, Inc. (NASDAQ:PRME) is a biotechnology company pioneering the field of gene editing with its Prime Editing technology. This next-generation technology allows precise and flexible ...